Valbiotis SA
Valbiotis SA is a biotechnology company focused on the discovery and development of plant-derived active ingredients for the pharmaceutical and nutraceutical industries.
Business. Valbiotis SA is a biotechnology and medical research company headquartered in France. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Valbiotis is primarily listed on the Euronext Paris under the ticker symbol ALVAL.PA. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Valbiotis SA is a biotechnology and medical research company headquartered in France. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Valbiotis is primarily listed on the Euronext Paris under the ticker symbol ALVAL.PA. Specific details regarding operating segments and geographic revenue mix are not available.
Valbiotis has a basic and diluted share count of 23.66 million shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and returns are not currently available for comparison against industry benchmarks, as no valuation snapshot data is provided. This lack of data limits the ability to assess Valbiotis's performance relative to its peers in the Biotechnology & Medical Research industry.
Valbiotis's revenue concentration and geographic exposure are not disclosed in the available data. The absence of segment and geographic breakdowns prevents a detailed analysis of the company's diversification and potential regional risks.
The company's growth trajectory is not quantified in the available data, as no outlook figures or revenue history are provided. Analysts have assigned a mean price target of 2.34 EUR and a median price target of 2.25 EUR, with a mean recommendation of 1.50 (leaning toward "strong buy").
Valbiotis faces a low dilution risk, with no significant dilution sources identified in the risk assessment. The company's liquidity risk remains unassessed, and no adjustments have been applied to valuation metrics.
No recent events, such as filings or transcripts, are available in the provided data to inform the company's current strategic direction or operational developments.
- Valbiotis has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
- Analysts have a generally positive outlook, with a mean recommendation of 1.50 and a median price target of 2.25 EUR.
- The company's liquidity risk is unassessed, and no balance-sheet inputs are available for evaluation.
- No segment or geographic revenue breakdown is provided, limiting the ability to assess diversification.
- No growth trajectory or revenue history is available, making forward-looking analysis challenging.
- No recent events or filings are disclosed, which may limit insight into the company's strategic direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €905.0k, +417,1% YoY; Operating income +8,9% YoY.
- ▍Revenue €905.0k, +417,1% YoY
- ▍Operating income +8,9% YoY
- ▍Net income +6,0% YoY
- ▍Free cash flow +4,8% YoY
- ▍Net margin -1040.7%
Revenue €175.0k, −96,3% YoY; Operating income −45,2% YoY.
- ▍Revenue €175.0k, −96,3% YoY
- ▍Operating income −45,2% YoY
- ▍Net income −36,1% YoY
- ▍Free cash flow −39,9% YoY
- ▍Net margin -5728.6%
Revenue €4.7M, +502,9% YoY; Operating income +40,3% YoY.
- ▍Revenue €4.7M, +502,9% YoY
- ▍Operating income +40,3% YoY
- ▍Net income +40,2% YoY
- ▍Free cash flow +41,8% YoY
- ▍Net margin -155.7%
Revenue €785.0k, +163,4% YoY; Operating income −41,9% YoY.
- ▍Revenue €785.0k, +163,4% YoY
- ▍Operating income −41,9% YoY
- ▍Net income −41,8% YoY
- ▍Free cash flow −45,8% YoY
- ▍Net margin -1568.4%
Revenue €298.0k; Operating income -€8.5M.
- ▍Revenue €298.0k
- ▍Operating income -€8.5M
- ▍Net margin -2913.1%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,36 |
| Revenue | —no estimate | —no estimate | 4,5M EUR |
| Operating income | —no estimate | —no estimate | -7,7M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Valbiotis SA Market data — financials · 2026-05-27
- Valbiotis SA Market data — analyst estimates · 2026-05-27